Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

BACKGROUND: In China, there are currently no approved therapies for the treatment of metastatic renal cell carcinoma (mRCC) following progression with vascular endothelial growth factor (VEGF)-targeted agents. In the phase 3 RECORD-1 trial, the mammalian target of rapamycin (mTOR) inhibitor everolim...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jun, Huang, Yiran, Zhang, Xu, Zhou, Fangjian, Sun, Yinghao, Qin, Shukui, Ye, Zhangqun, Wang, Hui, Jappe, Annette, Straub, Patrick, Pirotta, Nicoletta, Gogov, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626915/
https://www.ncbi.nlm.nih.gov/pubmed/23514360
http://dx.doi.org/10.1186/1471-2407-13-136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626915/
https://www.ncbi.nlm.nih.gov/pubmed/23514360
http://dx.doi.org/10.1186/1471-2407-13-136

Ejemplares similares